Market Overview

Endo Pharma Says FDA Issues CRL on Aveed NDA, Says Didn't Include Request for Added Trials

Share:
Related ENDP
Cantor Doesn't Think BioDelivery Sciences Should Be Cutting To Grow, Downgrades Stock To Hold
After-Hours Recap: Indexes Up Friday, But Still Down For The Week
Wally Weitz Sells Plunging Drug Stock Endo but Thinks It Has 'Upside Potential' (GuruFocus)

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA)  has issued a complete response letter regarding the New Drug Application (NDA) for Endo's long-acting testosterone undecanoate injection, AVEED™, for men diagnosed with hypogonadism.

The complete response letter did not include requests for the company to perform additional clinical studies.  The FDA outlined the steps necessary to support approval of the NDA and updated the requirement for a Risk Evaluation and Mitigation Strategy (REMS).  Specifically, the FDA has requested that the REMS include a Medication Guide as well as Elements to Assure Safe Use (ETASU) to mitigate the risks and severe complications related to post-injection reactions. 

Posted-In: News FDA

 

Related Articles (ENDP)

View Comments and Join the Discussion!